All News
Who declines most with #scleroderma #ILD - early dcSSc, ⬆️CRP, ⬆️mRSS all w more ⤵️FVC. Results verified in SENSIS trial of SSc ILD where #nintedanib was superior to placebo abst#1846 #ACR21 @RheumNow https://t.co/eckUj0qwch
Janet Pope Janetbirdope ( View Tweet)
Should we be measuring drug levels in pts taking infliximab?
⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO)
#ACR21
Abs#1946
#ACRBest @RheumNow
https://t.co/sWMen50ljP https://t.co/F4Wpqis3id
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in PsA on csDMARDs v #biologics #ACR21 abst#1833 @RheumNow https://t.co/TM91z5wiFY
Janet Pope Janetbirdope ( View Tweet)
So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm
Janet Pope Janetbirdope ( View Tweet)
Important late breaker @TerrierBen, DBRCT of RTX vs GC (FFS=0) or CYC (FFS>0) for EGPA
RTX not superior to CYC (64% RTX vs 60% CYC BVAS remission d180, p = 0.745); similar in subgroups
Feel like this lends support to (~surprising) ACR/VF recs for EGPA?
#ACR21 #ACRAmbassador https://t.co/gpsPtXF6pj
Mike Putman EBRheum ( View Tweet)
#ACR21 L19: TitAIN: Secukinumab for GCA
⭐️Phase 2 study with n=52
⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8%
⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g)
- Looking forward to larger study
@Rheumnow
https://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 L21. REOVAS: RTX for EGPA
⭐️CYC traditionally preferred for 5-factor score>0
▶️Remission rates and relapse-free survival comparable bw RTX and conventional. RTX not superior for induction
▶️No diff in ANCA+/-, naive v relapse, FFS
https://t.co/cuM9LcEr4u @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws
Dr. Rachel Tate uptoTate ( View Tweet)
RHEKISS registry: SpA pts on bDMARDs at conception are NOT at inc. risk for adverse pregnancy outcomes. Discontinuation of bDMARDs after conception is assoc'd w/ inc. dz activity during/after pregnancy & flare risk. Abs 1730 #ACR21 #RheumNow @RheumNow https://t.co/b2wI9GZios https://t.co/wsuvv3hF0v
Dr. Rachel Tate uptoTate ( View Tweet)
b/tsDMARDs + tumor response in rheum irAEs
Excellent point by @CCalabreseDO @LCalabreseDO:
- despite progression in 5/10, DMARD contribution uncertain (bad cancer)
- without DMARD, ICI would have had to stop
crucial question, prospective study needed
#ACR21 ABST1519 @RheumNow https://t.co/omJnTNVscH
David Liew drdavidliew ( View Tweet)
Sub-analysis of ICHIBAN study looking at adverse events in tocilizumab treated patients with/without steroids. Steroids associated with small increase in adverse events across board. Abstr#1693 #ACR21 @RheumNow https://t.co/ldiovirKpo
Richard Conway RichardPAConway ( View Tweet)
For patients with inflammatory irAEs, what's your preference of bDMARD/tsDMARD?
(keeping in mind both irAE response and tumor response)
#ACR21 irAE Study Group run by @CCalabreseDO @NAbdelwahabMD @ReidMDMPH
@RheumNow
David Liew drdavidliew ( View Tweet)
#ACR21 Ab#1655. Respiratory Ifn in RA on bDMARD
▶️1 group was initiated into vaccination program vs usual care
⭐️Vaccinated group had ⬇️ admissions from respiratory ifns. 44% ⬇️ severe resp ifn
💉programs work!
@Rheumnow https://t.co/pljR6DbAtU https://t.co/goSHGID8qG
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Year In Review: Factors associated with #COVID deaths in pts with #RMD:
⛔️age, male, HTN/CVD, lung disease, steroid>10mg/d, ⬆️disease activity
⛔️RTX (OR: 4), SFZ (3.6), other IS (2.2), No DMARDs (2.1) vs MTX monotherapy as reference @RheumNow https://t.co/Zd6qXCtGLk https://t.co/YHBEelLqKB
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Avacopan (C5a inhibitor) is a new promising therapy for ANCA vasculitis. US FDA approved in Oct 2021
#ACR21 @rheumnow https://t.co/tWvKzHOT5V
swethaann23 swethaann23 ( View Tweet)
Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
Richard Conway RichardPAConway ( View Tweet)
Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care
🔹Most common SoC Rx: MMF, Aza, and/or cyclophosphamide
🔹🚫significant diff
🔹RTX pts = ⬆️dz duration, ⬆️# of prior meds, ⬇️maintenance steroid dose
https://t.co/AYQFXqlubl
#ACR21 Abst1288 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
SLE: Belimumab + standard rx significantly⬇️risk of severe flares vs placebo.
Greatest in those with:
🔹+dsDNA
🔹low C3 or C4
🔹SLICC/ACR Damage index of 0 (argument for early treatment!)
https://t.co/UcGXEklqwJ
#ACR21 Abst#1295
@RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
#ACR21 Ab#1445. RTX & #covid19 outcomes
⭐️RTX ass. w/ Upwards arrow COVID hospitalization, ICU admission, and ventilation
▶️We need huge caution in pts that have not been vax'ed before RTX 💉💉
@Rheumnow
https://t.co/6UNUVhnBkI https://t.co/vHkQe9fZpI
Links:
Eric Dein ericdeinmd ( View Tweet)
So what do we do with Iberdomide data? Tough to analyze re 2nd half of yr1 and uncertainty of dose response Abst#1458 #ACR21 @RheumNow v low placebo response 35% Interesting https://t.co/JXnoJTy2tv
Janet Pope Janetbirdope ( View Tweet)